Tramadol

Tramadol Hydrochloride Injection (50mg/ml, 100mg/2ml) is an injectable central opioid analgesic on the WHO Model List of Essential Medicines. It binds to mu-opioid receptors and inhibits neuronal reuptake of norepinephrine and serotonin in spinal cord dorsal horn synapses. Indicated for moderate-to-severe acute pain, post-operative surgical pain, renal colic, and severe trauma pain where oral administration is unfeasible.

Tramadol Hydrochloride Injection (50mg/ml, 100mg/2ml) is an injectable central opioid analgesic on the WHO Model List of Essential Medicines. It binds to mu-opioid receptors and inhibits neuronal reuptake of norepinephrine and serotonin in spinal cord dorsal horn synapses. Indicated for moderate-to-severe acute pain, post-operative surgical pain, renal colic, and severe trauma pain where oral administration is unfeasible.

Tramadol Hydrochloride Tablets (50mg, 100mg Prolonged Release) is an oral centrally acting synthetic atypical opioid analgesic on the WHO Model List of Essential Medicines. It exerts a dual synergistic mechanism: parent drug and its active M1 metabolite bind to mu-opioid receptors, while parent tramadol inhibits reuptake of serotonin and norepinephrine, enhancing descending spinal inhibition. Indicated for management of moderate-to-moderately-severe acute and chronic pain.

Paracetamol (162.5mg/325mg) and Tramadol Hydrochloride (18.75mg/37.5mg) Tablets is a synergistic, multi-mechanistic analgesic combination on the WHO Model List framework for moderate-to-severe pain. Tramadol acts as a weak mu-opioid receptor agonist while simultaneously inhibiting the reuptake of norepinephrine and serotonin (5-HT) in the descending spinal pain inhibitory pathways. Paracetamol acts centrally to inhibit prostaglandin synthesis and activate descending serotonergic pathways. Combining them produces additive analgesia at lower individual doses with faster onset (paracetamol ~30 min) and extended duration (tramadol 6-8 hours). Indicated for management of moderate-to-severe acute pain, postoperative pain, acute musculoskeletal trauma, and severe osteoarthritis flares.

Tramadol Hydrochloride Tablets (50mg, 100mg Prolonged Release) is an oral centrally acting synthetic atypical opioid analgesic on the WHO Model List of Essential Medicines. It exerts a dual synergistic mechanism: parent drug and its active M1 metabolite bind to mu-opioid receptors, while parent tramadol inhibits reuptake of serotonin and norepinephrine, enhancing descending spinal inhibition. Indicated for management of moderate-to-moderately-severe acute and chronic pain.

Paracetamol (162.5mg/325mg) and Tramadol Hydrochloride (18.75mg/37.5mg) Tablets is a synergistic, multi-mechanistic analgesic combination on the WHO Model List framework for moderate-to-severe pain. Tramadol acts as a weak mu-opioid receptor agonist while simultaneously inhibiting the reuptake of norepinephrine and serotonin (5-HT) in the descending spinal pain inhibitory pathways. Paracetamol acts centrally to inhibit prostaglandin synthesis and activate descending serotonergic pathways. Combining them produces additive analgesia at lower individual doses with faster onset (paracetamol ~30 min) and extended duration (tramadol 6-8 hours). Indicated for management of moderate-to-severe acute pain, postoperative pain, acute musculoskeletal trauma, and severe osteoarthritis flares.

Tramadol Hydrochloride (50mg immediate-release) and Diclofenac Sodium (75mg sustained-release) Tablets combines a centrally acting dual-mechanism opioid with a potent peripheral non-steroidal anti-inflammatory drug (NSAID). Tramadol dampens central pain transmission via mu-opioid activation and monoaminergic reuptake inhibition; diclofenac blocks peripheral COX-1 and COX-2 enzymes to eliminate tissue inflammation and prostaglandin-mediated sensitization of nociceptors. Indicated for severe acute and chronic musculoskeletal pain, post-surgical orthopedic pain, and severe osteoarthritic/rheumatoid joint destruction.